

FDA Finalizes Interchangeable Biosimilar Advice, with Insulin Focus

May 13, 2019

ATTORNEYS

Ropka, PhD, Stacie

Andrew Dunn

BioPharma Dive

PRACTICE AREAS

FDA

Axinn partner Stacie Ropka was quoted in the *BioPharma Dive* article, "FDA Finalizes Interchangeable Biosimilar Advice, with Insulin Focus."

Click [here](#) to access the article.